Aktie A12FJ4 PARADIGM BIOPHARMACEUTICALS LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Paradigm Biopharmaceuticals Limited

Aktien

A12FJ4

AU000000PAR5

PAR

Markt geschlossen - Australian S.E.
Andere Börsenplätze
 08:10:50 05.07.2024 		% 5 Tage % 1. Jan.
0,29 AUD -1,69 % Intraday Chart für Paradigm Biopharmaceuticals Limited +11,54 % -31,76 %
28.02. Paradigm Biopharmaceuticals Limited meldet Gewinnergebnisse für das am 31. Dezember 2023 endende Halbjahr CI
12.02. Paradigm Biopharma's injizierbare Pentosan Polysulfat-Natrium-Studie erreicht den Endpunkt MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial
Starpharma Appoints CFO
Paradigm Biopharmaceuticals Names Interim CFO
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A12FJ4 Aktie
  4. Nachrichten Paradigm Biopharmaceuticals Limited
  5. Andere Sprachen